Stocks › INVA
Innoviva, Inc.
INVA·Nasdaq·
United States·USD
$18.41
+0.00 (+0.00%)
Close · Nov 20, 2026 · Close Prices from Tiingo.com
INVA
Innoviva, Inc. · Nasdaq
Nasdaq 100S&P 500
Filings
Default90D1Y5YALL
INVAS&P 500 (rebased)
Congress BuyCongress SellInsider BuyInsider SellForm 1448-K ResultsLobbying
Loading price history…
Daily closes, adjusted for splits and dividends · Close Prices from Tiingo.comHover a marker, every one is a filing · move across the line for the crosshair
Congressional Trades
Recent trades of INVA by members of U.S. Congress · 2 on record
| Politician | Stock | Type | Filed | Traded | |
|---|---|---|---|---|---|
George WhitesidesHouse · D · CA |
INVAInnoviva, Inc. · Stock |
Sale $250,001 - $500,000 |
Apr 23, 2025 | Mar 25, 2025 | Filing ↗ |
George WhitesidesHouse · D · CA |
INVAInnoviva, Inc. · Stock |
Sale $50,001 - $100,000 |
Apr 23, 2025 | Mar 24, 2025 | Filing ↗ |
Whale Activity
Position changes in INVA reported for 2026-09-30 by 344 institutional filers
- Increased108
- New36
- Held37
- Decreased92
- Closed50
- No prior filing21
| Filer | Shares | Value | Change |
|---|---|---|---|
| BlackRock, Inc. | 12.6M | $266.4M | increased |
| DIMENSIONAL FUND ADVISORS LP | 4.5M | $95.7M | increased |
| VANGUARD PORTFOLIO MANAGEMENT LLC | 4.2M | $88.6M | decreased |
| RENAISSANCE TECHNOLOGIES LLC | 3.7M | $77.4M | decreased |
| STATE STREET CORP | 3.5M | $74.2M | increased |
| VANGUARD CAPITAL MANAGEMENT LLC | 3.2M | $67.3M | increased |
| MILLENNIUM MANAGEMENT LLC | 2.6M | $54.3M | increased |
| SYSTEMATIC FINANCIAL MANAGEMENT LP | 2.1M | $43.8M | increased |
| GEODE CAPITAL MANAGEMENT, LLC | 2.1M | $43.7M | decreased |
| Sarissa Capital Management LP | 1.9M | $40.1M | held |
| MORGAN STANLEY | 1.7M | $36.5M | increased |
| GOLDMAN SACHS GROUP INC | 1.6M | $34.4M | increased |
Every 13F filer's complete reported book, every quarter since 2013-06-30. 13F itself excludes short positions, cash and most options.
Insider Trading
Net shares bought (+) or sold (−) on the open market by INVA insiders, by quarter · Form 4
Recent Insider Transactions
265 transactions on record · newest first
| Insider | Type | Shares | Price | Value | Date | |
|---|---|---|---|---|---|---|
| Zhen MarianneChief Accounting Officer | Tax withholding | −1,127 | $21.00 | $24K | Aug 20, 2026 | Form 4 ↗ |
| Basso StephenChief Financial Officer | Tax withholding | −558 | $21.00 | $12K | Aug 20, 2026 | Form 4 ↗ |
| Raifeld PavelChief Executive Officer · Director | Tax withholding | −1,130 | $21.00 | $24K | Aug 20, 2026 | Form 4 ↗ |
| Basso StephenChief Financial Officer | Tax withholding | −559 | $22.24 | $12K | May 20, 2026 | Form 4 ↗ |
| Raifeld PavelChief Executive Officer · Director | Tax withholding | −1,130 | $22.24 | $25K | May 20, 2026 | Form 4 ↗ |
| Zhen MarianneChief Accounting Officer | Tax withholding | −1,127 | $22.24 | $25K | May 20, 2026 | Form 4 ↗ |
| Linden JosephineDirector | Grant / award | +9,461 | $0.00 | $0 | May 18, 2026 | Form 4 ↗ |
| Linden JosephineDirector | Grant / award | +5,733 | $0.00 | $0 | May 18, 2026 | Form 4 ↗ |
| Basso StephenChief Financial Officer | Grant / award | +1,123 | $0.00 | $0 | May 15, 2026 | Form 4 ↗ |
| Raifeld PavelChief Executive Officer · Director | Grant / award | +1,123 | $0.00 | $0 | May 15, 2026 | Form 4 ↗ |
| DiPaolo MarkDirector | Grant / award | +9,786 | $0.00 | $0 | May 4, 2026 | Form 4 ↗ |
| Raifeld PavelChief Executive Officer · Director | Grant / award | +126.6K | $0.00 | $0 | May 4, 2026 | Form 4 ↗ |
| Zhen MarianneChief Accounting Officer | Grant / award | +12.8K | $0.00 | $0 | May 4, 2026 | Form 4 ↗ |
| Schlesinger Sarah J.Director | Grant / award | +9,786 | $0.00 | $0 | May 4, 2026 | Form 4 ↗ |
| Basso StephenChief Financial Officer | Grant / award | +38.0K | $0.00 | $0 | May 4, 2026 | Form 4 ↗ |
| Small Derek ADirector | Grant / award | +9,786 | $0.00 | $0 | May 4, 2026 | Form 4 ↗ |
| Haimovitz JulesDirector | Grant / award | +9,786 | $0.00 | $0 | May 4, 2026 | Form 4 ↗ |
| Basso StephenChief Financial Officer | Tax withholding | −1,244 | $23.39 | $29K | Feb 20, 2026 | Form 4 ↗ |
| Raifeld PavelChief Executive Officer · Director | Tax withholding | −2,986 | $23.39 | $70K | Feb 20, 2026 | Form 4 ↗ |
| Zhen MarianneChief Accounting Officer | Tax withholding | −2,460 | $23.39 | $58K | Feb 20, 2026 | Form 4 ↗ |
Fund Holders
Mutual funds and ETFs holding INVA · SEC Form N-PORT
| Fund | Shares | Value | % of fund | As of |
|---|---|---|---|---|
| iShares Core S&P Small-Cap ETF iShares Trust | 4.2M | $96.0M | 0.09% | Jun 30, 2026 |
| VANGUARD TOTAL STOCK MARKET INDEX FUND VANGUARD INDEX FUNDS | 2.2M | $50.7M | 0.00% | Jun 30, 2026 |
| iShares Russell 2000 ETF iShares Trust | 1.9M | $44.1M | 0.05% | Jun 30, 2026 |
| VANGUARD SMALL-CAP INDEX FUND VANGUARD INDEX FUNDS | 1.6M | $36.5M | 0.02% | Jun 30, 2026 |
| VANGUARD SMALL-CAP VALUE INDEX FUND VANGUARD INDEX FUNDS | 1.0M | $23.1M | 0.03% | Jun 30, 2026 |
| U.S. SMALL CAP VALUE PORTFOLIO DFA INVESTMENT DIMENSIONS GROUP INC | 1.0M | $21.1M | 0.11% | Jul 31, 2026 |
| VANGUARD EXTENDED MARKET INDEX FUND VANGUARD INDEX FUNDS | 803.3K | $18.2M | 0.02% | Jun 30, 2026 |
| Avantis U.S. Small Cap Value ETF American Century ETF Trust | 847.3K | $17.6M | 0.06% | Aug 31, 2026 |
| Fidelity Small Cap Index Fund Fidelity Salem Street Trust | 825.8K | $17.3M | 0.05% | Jul 31, 2026 |
| iShares Russell 2000 Value ETF iShares Trust | 707.3K | $16.1M | 0.11% | Jun 30, 2026 |
Mutual funds and ETFs whose N-PORT filings list INVA's shares (CUSIP 45781M101), each fund at its latest report since Apr 22, 2026, largest positions first. Bonds, options and short positions are left out.
Corporate Lobbying
Estimated quarterly lobbying spending reported under the LDA, filings naming Innoviva, Inc. as client
No lobbying filings found naming Innoviva, Inc. as the client.
Government Contracts
Federal awards to Innoviva, Inc. · USAspending
No federal contract awards found for Innoviva, Inc..
U.S. Patents
Recent USPTO applications naming Innoviva, Inc.
No USPTO patent applications found for Innoviva, Inc..
Annual Financials
From INVA's 10-K filings · XBRL
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | $411.3M | $358.7M | $310.5M | $331.3M | $391.9M |
| Operating income | $163.7M | $166.9M | $113.9M | n/a | $375.1M |
| Diluted EPS | $3.30 | $0.36 | $2.20 | $2.37 | $2.87 |
| Operating cash flow | $196.9M | $188.7M | $141.1M | $201.7M | $363.8M |
| Cash and equivalents | $550.9M | $305.0M | $193.5M | $291.0M | $201.5M |
| Total assets | $1.64B | $1.30B | $1.24B | $1.23B | $926.4M |
| Shareholders' equity | $1.17B | $691.2M | n/a | $565.8M | $414.7M |
As Innoviva, Inc. tagged them in its 10-K filings: totals for the year on the income and cash-flow lines, values at the year's end on the balance-sheet lines. Latest 10-K, filed Feb 25, 2026 ↗
Stock Splits
Every split and reverse split in the price history
No stock splits in INVA's price history.
Material Events (8-K)
Corporate events filed with the SEC
About Innoviva, Inc.
From SEC EDGAR company records
Industry (SIC 2834)Pharmaceutical Preparations
SectorHealthcare
HeadquartersBURLINGAME, CA
IncorporatedDE
SEC CIK0001080014 ↗
Former namesTHERAVANCE INC, ADVANCED MEDICINE INC

